Pharmacokinetic/Toxicodynamic Analysis of Colistin-Associated Acute Kidney Injury in Critically Ill Patients-Reference-Cited by-同舟云学术

Pharmacokinetic/Toxicodynamic Analysis of Colistin-Associated Acute Kidney Injury in Critically Ill Patients

Published:2017-11 Issue:11 Volume:61 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Forrest Alan¹,Garonzik Samira M.¹,Thamlikitkul Visanu²,Giamarellos-Bourboulis Evangelos J.³^ORCID,Paterson David L.⁴,Li Jian⁵,Silveira Fernanda P.⁶,Nation Roger L.⁵

Affiliation:

1. School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, SUNY, Buffalo, New York, USA

2. Division of Infectious Diseases and Tropical Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

3. 4th Department of Internal Medicine, University of Athens, Medical School, Athens, Greece

4. The University of Queensland Center for Clinical Research, Royal Brisbane and Women's Hospital, Brisbane, Australia

5. Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia

6. Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Abstract

ABSTRACT Acute kidney injury (AKI) occurs in a substantial proportion of critically ill patients receiving intravenous colistin. In the pharmacokinetic/toxicodynamic analysis reported here, the relationship of the occurrence of AKI to exposure to colistin and a number of potential patient factors was explored in 153 critically ill patients, none of whom were receiving renal replacement therapy. Tree-based modeling revealed that the rates of AKI were substantially higher when the average steady-state plasma colistin concentration was greater than ∼2 mg/liter.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01367-17

Reference26 articles.

1. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus

2. The safety of polymyxin antibiotics

3. Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?

4. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Predictive Equation for the Estimation of Plasma Concentrations of Formed Colistin in Patients Treated With Colistimethate Sodium for Multidrug-Resistant Gram-Negative Bacterial Infections;Therapeutic Drug Monitoring;2024-07-09

2. Modification of the Antibiotic, Colistin, with Dextrin Causes Enhanced Cytotoxicity and Triggers Apoptosis in Myeloid Leukemia;International Journal of Nanomedicine;2024-06

3. Genetic predisposition and high exposure to colistin in the early treatment period as independent risk factors for colistin‐induced nephrotoxicity;Clinical and Translational Science;2024-03

4. Colistin plasma concentrations are not associated with better clinical outcomes in patients with pneumonia caused by extremely drug-resistant Pseudomonas aeruginosa;Microbiology Spectrum;2023-12-12

5. Modification of the antibiotic, colistin, with dextrin causes enhanced cytotoxicity and triggers apoptosis in myeloid leukemia;2023-11-13